Cloudways Demonstrates Growth Ambitions with Customer Momentum, New Features, and Key Executive Hires
2.6.2022 10:00:00 EEST | Business Wire | Press release
Cloudways (cloudways.com), the leading cloud hosting provider focused on simplicity, flexibility, and performance, announces significant customer momentum ahead of their presence at WordCamp Europe. Cloudways’ announcements at WordCamp Europe include SafeUpdates (in beta), new automations that manage WordPress updates at scale, and partnership with Astra Pro, a collaboration allowing users to build websites faster and easier than ever before.
Cloudways supports over 70k customers and 500K+ websites and was recently rated by G2 as the best cloud hosting company for SMBs with a rating of 4.8 out of 5. Additionally, Cloudways has strengthened its executive team with the hire of ex-Microsoft executive Paul Haverstock as VP of Engineering, Bluehost executive Suhaib Zaheer as COO, and AWS executive Tom Erskine as CMO. Cloudways has significantly grown in size to more than 280 employees, with its global mindset reflected in an employee base coming from 20+ countries.
Cloudways focuses on giving agencies, SMBs, e-commerce providers, and individuals a hassle-free, premium experience to help them grow their business with both peace of mind and improved productivity. The Cloudways platform features >99.9% uptime, fast page load times, pro-active app monitoring, dedicated workflows, leading security with add-ons from Cloudflare, and 24/7 premium support. Great value and flexibility are also key platform features with pay-as-you-go plans offered from cloud providers including AWS, Google Cloud, Linode, Vultur, and Digital Ocean and a choice of 65+ Data Center locations.
SafeUpdates, which is being launched in beta, is Cloudways’ newest feature and will enable agencies and developers to update their WordPress websites both automatically and on demand. The workflow secures a backup, performs advanced visual regression testing and performance checks on both staging and live, and then deploys selected updates to production or automatically rolls back the changes in case of any issues. SafeUpdates allows agencies and developers to automate their work, focus on their business, and upsell maintenance services with confidence.
Cloudways’ partnership with Astra Pro is part of a series of collaborations the company has made in recent months to enhance WordPress simplicity and ensure maximum performance and security on its platform. Cloudways has worked closely with Cloudflare, OceanWP, Divi, and OCP among others to offer a seamless, no-code digital experience for agencies and developers to build and secure WordPress websites.
“Cloudways is both growing as a company and building significant momentum in the cloud hosting industry,” said Aaqib Gadit, Co-Founder and CEO of Cloudways. “The recent addition of Suhaib, Tom, and Paul to our leadership team shows the growth plans and ambition we have for Cloudways. At Cloudways, we are deeply focused on being a trusted partner to our customers and are continually innovating to save them both time and money while delivering a great user experience.”
To learn more, visit Cloudways’ booth at WordCamp Europe at https://www.cloudways.com/en/wordcamp-europe.php
About Cloudways:
Founded in 2012, Cloudways is an intuitive, one-click managed cloud hosting platform that hosts over 50,000 servers globally. G2’s Best Managed Hosting Provider for 2021, the platform lets users host WordPress and WooCommerce websites on top of a variety of cloud-hosting providers, including Google Cloud, Amazon Web Services, DigitalOcean, Vultr, and Linode. The platform features a web app management function that easily launches cloud servers for the deployment of WordPress, Magento, and PHP. Visit the company website at https://www.cloudways.com/en/about_us.php
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005120/en/
Contact information
Cloudways Media Contact:
Lauren Perry
SlicedBrand for Cloudways
lauren@slicedbrand.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom